This transcript has been edited for clarity.
Hi. It's Dr Kathy Miller from Indiana University. I just finished a phenomenal science weekend at the European Society for Medical Oncology (ESMO) virtual congress, and I want to share some of the breast cancer data with you.
I remember being taught early in my career that a hallmark of good science, whether it's conducted in a laboratory or in the clinic, is that it forces you to ask more questions than it answers. And if that is the case, we saw some really good science this weekend. I want to review two sets of studies with you that have seemingly similar study designs but came to dramatically different conclusions.
First, let's think about the cyclin-dependent kinase (CDK) inhibitors in the adjuvant setting.
We saw the results of the PALLAS trialthat studied over 4000 largely stage II and III patients (about 1000 had stage IIA disease, so lymph node–negative patients were allowed to enroll) who were randomized to 2 years of palbociclib or not. It was stopped for futility at the second interim analysis. To be clear, the study was not stopped, but the data monitoring committee suggested that all patients still on palbociclib should stop therapy and enter follow-up.
COMMENTARY
CDK4/6 Inhibitors in Early Breast Cancer: Different Trial Results Means Good Science
Kathy D. Miller, MD
DisclosuresOctober 07, 2020
This transcript has been edited for clarity.
Hi. It's Dr Kathy Miller from Indiana University. I just finished a phenomenal science weekend at the European Society for Medical Oncology (ESMO) virtual congress, and I want to share some of the breast cancer data with you.
I remember being taught early in my career that a hallmark of good science, whether it's conducted in a laboratory or in the clinic, is that it forces you to ask more questions than it answers. And if that is the case, we saw some really good science this weekend. I want to review two sets of studies with you that have seemingly similar study designs but came to dramatically different conclusions.
First, let's think about the cyclin-dependent kinase (CDK) inhibitors in the adjuvant setting.
We saw the results of the PALLAS trialthat studied over 4000 largely stage II and III patients (about 1000 had stage IIA disease, so lymph node–negative patients were allowed to enroll) who were randomized to 2 years of palbociclib or not. It was stopped for futility at the second interim analysis. To be clear, the study was not stopped, but the data monitoring committee suggested that all patients still on palbociclib should stop therapy and enter follow-up.
Medscape Oncology © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Kathy D. Miller. CDK4/6 Inhibitors in Early Breast Cancer: Different Trial Results Means Good Science - Medscape - Oct 07, 2020.
Tables
Authors and Disclosures
Authors and Disclosures
Author(s)
Kathy D. Miller, MD
Professor of Medicine, Indiana University School of Medicine; Co-director, Breast Cancer Program, Indiana University Simon Cancer Center, Indianapolis, Indiana
Disclosure: Kathy D. Miller, MD, has disclosed no relevant financial relationships.